Impact of Simplera Sync™ sensors and Extended™ Wear Infusion Sets on glycaemia and system performance of the MiniMed™ 780G system in children and young adults with previously high HbA1c.

IF 3.2 3区医学 Q2 ENDOCRINOLOGY & METABOLISM

Diabetic Medicine Pub Date : 2025-04-18 DOI:10.1111/dme.70048

Venus R Michaels, Alisa Boucsein, Yongwen Zhou, Shirley D Jones, Ryan G Paul, Esko Wiltshire, Craig Jefferies, Martin I de Bock, Benjamin J Wheeler

{"title":"Impact of Simplera Sync™ sensors and Extended™ Wear Infusion Sets on glycaemia and system performance of the MiniMed™ 780G system in children and young adults with previously high HbA1c.","authors":"Venus R Michaels, Alisa Boucsein, Yongwen Zhou, Shirley D Jones, Ryan G Paul, Esko Wiltshire, Craig Jefferies, Martin I de Bock, Benjamin J Wheeler","doi":"10.1111/dme.70048","DOIUrl":null,"url":null,"abstract":"Aims: The MiniMed™ 780G improves glycaemia and reduces burden in type 1 diabetes. We investigated how new all-in-one \"Simplera Sync™\" sensors and 7-day Extended™ Wear Infusion Sets (EIS) affect glycaemia and system performance in young people with previously elevated HbA1c levels (≥69 mmol/mol [≥8%]) after transitioning from 780G with Guardian 4™ sensors and 3-day infusion sets.Methods: We conducted an extension phase analysis in 75 participants (aged 7-25 years) initially enrolled in the CO-PILOT randomised controlled trial. For this analysis, baseline was defined as the period following the use of 780G with Guardian 4™ sensors and 3-day infusion sets. Participants then transitioned to 780G with Simplera Sync™ and EIS. We compared glycaemic and system performance outcomes from baseline to those after the transition to 780G with Simplera Sync™ and EIS.Results: Baseline HbA1c was 66.1 mmol/mol ± 14.2 mmol/mol and remained stable at 66.7 mmol/mol ± 11.2 mmol/mol after the transition (p = 0.38). Time in range (3.9-10.0 mmol/L [70-180 mg/dL]) at baseline was 58.5% ± 14.9% and 60.4% ± 15.7% after transition (p = 0.09). Time in tight range (3.9-7.8 mmol/L [70-140 mg/dL]) increased from 38.1% ± 13.1% at baseline to 40.5% ± 13.6% after the transition (p = 0.04). While using 780G with Simplera Sync™ and EIS, automation time increased from baseline 79.2% ± 25.9% to 85.8% ± 21.8% (p = 0.007), and sensor wear time from 80.7% ± 22.4% at baseline to 88.4% ± 17.2% (p < 0001).Conclusions: Simplera Sync™ and EIS improved time in automation and sensor wear time when using 780G AHCL in this high-risk young population. This was associated with incremental improvement in time in tight range despite the challenges of this population.","PeriodicalId":11251,"journal":{"name":"Diabetic Medicine","volume":" ","pages":"e70048"},"PeriodicalIF":3.2000,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetic Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/dme.70048","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Aims: The MiniMed™ 780G improves glycaemia and reduces burden in type 1 diabetes. We investigated how new all-in-one "Simplera Sync™" sensors and 7-day Extended™ Wear Infusion Sets (EIS) affect glycaemia and system performance in young people with previously elevated HbA1c levels (≥69 mmol/mol [≥8%]) after transitioning from 780G with Guardian 4™ sensors and 3-day infusion sets.

Methods: We conducted an extension phase analysis in 75 participants (aged 7-25 years) initially enrolled in the CO-PILOT randomised controlled trial. For this analysis, baseline was defined as the period following the use of 780G with Guardian 4™ sensors and 3-day infusion sets. Participants then transitioned to 780G with Simplera Sync™ and EIS. We compared glycaemic and system performance outcomes from baseline to those after the transition to 780G with Simplera Sync™ and EIS.

Results: Baseline HbA1c was 66.1 mmol/mol ± 14.2 mmol/mol and remained stable at 66.7 mmol/mol ± 11.2 mmol/mol after the transition (p = 0.38). Time in range (3.9-10.0 mmol/L [70-180 mg/dL]) at baseline was 58.5% ± 14.9% and 60.4% ± 15.7% after transition (p = 0.09). Time in tight range (3.9-7.8 mmol/L [70-140 mg/dL]) increased from 38.1% ± 13.1% at baseline to 40.5% ± 13.6% after the transition (p = 0.04). While using 780G with Simplera Sync™ and EIS, automation time increased from baseline 79.2% ± 25.9% to 85.8% ± 21.8% (p = 0.007), and sensor wear time from 80.7% ± 22.4% at baseline to 88.4% ± 17.2% (p < 0001).

Conclusions: Simplera Sync™ and EIS improved time in automation and sensor wear time when using 780G AHCL in this high-risk young population. This was associated with incremental improvement in time in tight range despite the challenges of this population.

查看原文本刊更多论文

Simplera Sync™传感器和Extended™穿戴式输液器对先前患有高HbA1c的儿童和年轻人的血糖和MiniMed™780G系统性能的影响

目的：MiniMed™780G改善1型糖尿病患者的血糖，减轻患者负担。我们研究了新的一体化“Simplera Sync™”传感器和7天延长™穿戴式输液器（EIS）如何影响先前HbA1c水平升高（≥69 mmol/mol[≥8%]）的年轻人在使用Guardian 4™传感器和3天输液器从780G过渡后的血糖和系统性能。方法：我们对最初加入CO-PILOT随机对照试验的75名参与者（7-25岁）进行了扩展期分析。在本分析中，基线定义为使用带有Guardian 4™传感器的780G和3天输液器后的时期。然后，参与者使用Simplera Sync™和EIS过渡到780G。我们使用Simplera Sync™和EIS比较了从基线到780G后的血糖和系统性能结果。结果：基线HbA1c为66.1 mmol/mol±14.2 mmol/mol，转变后稳定在66.7 mmol/mol±11.2 mmol/mol （p = 0.38）。基线时（3.9-10.0 mmol/L [70-180 mg/dL]）的时间为58.5%±14.9%，转化后为60.4%±15.7% （p = 0.09）。紧张范围（3.9-7.8 mmol/L [70-140 mg/dL]）的时间从基线时的38.1%±13.1%增加到过渡后的40.5%±13.6% （p = 0.04）。780G联合使用Simplera Sync™和EIS时，自动化时间从基线的79.2%±25.9%增加到85.8%±21.8% (p = 0.007)，传感器磨损时间从基线的80.7%±22.4%增加到88.4%±17.2% (p)。结论：在该高危青年人群中，使用780G AHCL时，Simplera Sync™和EIS改善了自动化时间和传感器磨损时间。尽管这一人群面临挑战，但这与时间上的渐进改善有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetic Medicine 医学-内分泌学与代谢

CiteScore

7.20

自引率

5.70%

发文量

229

审稿时长

3-6 weeks

期刊介绍： Diabetic Medicine, the official journal of Diabetes UK, is published monthly simultaneously, in print and online editions. The journal publishes a range of key information on all clinical aspects of diabetes mellitus, ranging from human genetic studies through clinical physiology and trials to diabetes epidemiology. We do not publish original animal or cell culture studies unless they are part of a study of clinical diabetes involving humans. Categories of publication include research articles, reviews, editorials, commentaries, and correspondence. All material is peer-reviewed. We aim to disseminate knowledge about diabetes research with the goal of improving the management of people with diabetes. The journal therefore seeks to provide a forum for the exchange of ideas between clinicians and researchers worldwide. Topics covered are of importance to all healthcare professionals working with people with diabetes, whether in primary care or specialist services. Surplus generated from the sale of Diabetic Medicine is used by Diabetes UK to know diabetes better and fight diabetes more effectively on behalf of all people affected by and at risk of diabetes as well as their families and carers.”